Sublingual immunotherapy with house dust mite allergen [house dust mite extract] in children with allergic rhinitis: randomised double-blind placebo-controlled trial.

Trial Profile

Sublingual immunotherapy with house dust mite allergen [house dust mite extract] in children with allergic rhinitis: randomised double-blind placebo-controlled trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2012

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic rhinitis
  • Focus Therapeutic Use
  • Acronyms STARDROP-II
  • Sponsors Artu Biologicals Europe
  • Most Recent Events

    • 08 May 2012 New source identified and integrated (Netherlands Trial Register; NTR385).
    • 18 Aug 2009 Additional lead trial centres and investigators identified as reported by ISRCTN: Current Controlled Trials.
    • 31 Dec 2008 Status is now completed, according to ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top